camoteskimab 
GtoPdb Ligand ID: 13187
|
Synonyms: AEVI 007 | AEVI-007 | AVTX 007 | AVTX-007 | CERC 007 | CERC-007 | MEDI 2338
Compound class:
Antibody
Comment: Camoteskimab (Apollo Therapeutics) is a fully human IgG1 monoclonal antibody that targets the proinflammatory cytokine interleukin-18 (IL-18). It has anti-inflammatory actions for application in autoinflammatory diseases.
|
| No information available. |
Summary of Clinical Use  |
| The FDA granted orphan designation in February 2024, for the treatment of adult-onset Still's disease and systemic juvenile idiopathic arthritis [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04752371 | A Study to Evaluate Camoteskimab in Participants With Still's Disease | Phase 1 Interventional | Apollo Therapeutics Ltd | ||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License